Facioscapulohumeral muscular dystrophy (FSH) …

Neuromuscular Disorders

Updated 07.02.2024
Released 03.09.1995
Expires For CME 07.02.2027

Facioscapulohumeral muscular dystrophy

Authors: Leo H Wang MD PhD, Matthew Preston MD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Facioscapulohumeral muscular dystrophy

In This Article

Quick Link

Introduction

Overview

Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly inherited, clinically recognizable, and relatively common muscular dystrophy. It does not generally curtail longevity but causes significant morbidity: about 20% of patients use a wheelchair after the age of 50. The differential diagnosis includes a subset of limb-girdle muscular dystrophies, scapuloperoneal myopathy/muscular dystrophy/neuronopathy, and rare mitochondrial myopathies. The molecular genetic mechanism of facioscapulohumeral muscular dystrophy is due to an unusual toxic gain-of-function in which the normally repressed transcription factor DUX4 is now expressed in muscle cells. The authors describe the clinical features and the molecular mechanism underlying the disease and potentially promising therapeutic approaches because of the elucidated molecular mechanism.

Key points

	• Facioscapulohumeral muscular dystrophy (FSHD) can be recognized by inspection and clinical examination; the diagnosis can be confirmed by genetic testing.
	• Differential diagnosis is limited to few other conditions. Restrictive lung disease is infrequent but can result in significant morbidity. However, life expectancy is almost normal.
	• Inheritance is autosomal dominant in most with a high incidence of sporadic cases due to de novo mutations.
	• Although genetically distinct, both FSHD1 and FSHD2 result from expression of a normally silenced gene, DUX4.
	• Drug treatment is not available, but targeted therapeutic trials are ongoing.
	• Scapular fixation can be helpful.
	• Published evidence-based care guidelines provide useful information for managing facioscapulohumeral muscular dystrophy and its potential complications.

Historical note and terminology

Landouzy and Dejerine described the disease and gained the eponym (40) even though Duchenne had earlier published a photograph of a patient with the classic features (15). Justin-Bescanon described three later generations in the Landouzy-Dejerine family, including the autopsy of one of the original patients who died at 86 years of age (34). These original reports remain astute descriptions of the disease, describing the autosomal dominant pattern of inheritance, the protean clinical manifestation, including the mild course of many affected family members, with one of their patients having evident facial weakness at 9 years of age but did not have symptomatic limb weakness until 60 years of age.

Comprehensive reviews (52) and a multi-authored monograph (99) summarize all of the clinical aspects of facioscapulohumeral muscular dystrophy in detail. AAN guidelines now provide evidence-based guidelines for the management of facioscapulohumeral muscular dystrophy (85).

Clinical manifestations

Presentation and course

Typical manifestations. Symptoms in most patients become evident in late childhood or adolescence. Protruding scapulae (winging) may be noted by the caregivers of the child, especially if they had previously seen other affected family members. The next manifestation is likely to be difficulty raising the arms, often asymmetrically. Difficulty lifting objects may follow. Sometimes, the distortion of shoulder girdle structures makes it difficult for the person to dress in shirts, blouses, or jackets. The disorder progresses slowly to include truncal muscles as well as lower extremity muscles. If there is leg weakness, it is apt to be initially more distal than proximal, so there is a tendency for a foot-drop gait. This gives rise to a scapuloperoneal distribution of limb weakness. Facial weakness may be less of a complaint, with many individuals retrospectively stating that they have never been able to whistle or suck from a straw. Most dramatically and rarely, some patients may sleep with their eyes open.

Signs on examination parallel the distribution of weakness. Weakness of eye closure is sometimes manifested by a wide-eyed appearance or inability to close the eyes against resistance. The lips tend to be full or even slightly everted. There is also loss of wrinkles overlying the affected facial muscles. The most dramatic set of signs is caused by inability to fix the scapulae. At rest, the scapulae deviate laterally. There may be winging of the scapulae with the arms dependent, in attempts to raise the arms to shoulder level by abducting the arms, or in pushing against a wall with the hands at shoulder level and elbows straight.

Scapular winging and poly-hill sign in facioscapulohumeral muscular dystrophy

(Contributed by Dr. Leo Wang.)

Viewed from in front of the patient, the tips of the scapulae rise above the clavicle, presenting a typical facioscapulohumeral appearance. The distinctive picture may be augmented by poorly developed pectoral muscles or frank pectus excavatum, so that the chest seems to be caved-in. If the pectorals are severely wasted, the anterior axillary fold, which is formed by the pectorals and normally runs at a diagonal from the chest to the head of the humerus, is lost, and the fold is either vertical or even reversed.

As a result of the scapular disorder, the arms cannot be raised to shoulder level even before there is detectable weakness of the supraspinati, infraspinati, or deltoids on manual muscle tests. The unusual pattern of bumps and depressions from protruding bones and preserved muscle alternating with small muscles has been called the “poly-hill” sign (65).

Weakness of muscles in the anterior compartment of the legs may be detected even before there is an abnormality of gait. Tendon reflexes may be either preserved or absent in weaker individuals.

The abdominal muscles are often affected, resulting in a protuberant abdomen and difficulty sitting up from a supine position. The Beevor sign, which is upward movement of the umbilicus on flexion of the neck, is attributed to selective weakness of the lower part of the rectus abdominus so that the upper fibers are stronger and pull the umbilicus upward (16). The sign was present in 15 of 28 patients with FSHD, as compared to two of 65 patients with other myopathies. Given its specificity in FSHD, a positive Beevor sign can be a useful early diagnostic sign in patients without overt abdominal muscle weakness.

Spectrum of disease manifestations. Early-onset FSHD was reported to occur in up to 21% of patients in one review (26). Early-onset was defined as age of onset of facial weakness (before 5) and shoulder girdle weakness (before 10). These patients can present with more severe muscle weakness and more rapid progression. Approximately half the patients will have systemic features (including hearing loss, retinal abnormalities, respiratory insufficiency, and developmental delay). De novo/sporadic cases are more likely in this population (26). However, the classification of early onset FSHD was, in many cases, based on recall in adults with FSHD, which likely introduced a selection bias overestimating the true incidence of early onset FSHD. In a more unbiased nationwide, prospective, cross-sectional study, patients less than 17 years old resembled classic FSHD in presentation and genetics (24). Furthermore, long-term follow-up of these patients also suggest a heterogeneous disease course (25), with mild and slow progression of facial weakness, pain, fatigue, and lumbar hyperlordosis after two years (13).

In addition to age of onset, disease severity is broadly influenced by the number of the residual D4Z4 repeats on chromosome 4 (see genetics).

Similarly, adult-onset forms may also be severely affected; in some series, about 20% of adults over the age of 50 lose the ability to walk and are in wheelchairs (60).

Many affected individuals in a family are asymptomatic but show unequivocal signs of the dystrophy on examination (98). About 30% of all familial cases are asymptomatic. If the parents of an affected person are clinically normal and do not show the typical molecular changes associated with FSHD, and if more than one sibling is affected, a de novo mutation in the germline is suspected (36). Alternatively, one of the parents is a somatic mosaic for the FSHD mutation with minimal or no symptoms of FSHD. At least 12% of familial cases have normal neurologic examination, have no symptoms, and are nonpenetrant FSHD1 carriers (106).

Hearing loss and retinal vascular disease are associated with facioscapulohumeral muscular dystrophy, but they are rarely symptomatic except in the more severely affected individuals, almost exclusively most commonly in childhood-onset facioscapulohumeral muscular dystrophy (05; 58). Studies confirm that symptomatic retinal vasculopathy and hearing loss happen almost exclusively and occur in individuals with large deletions, with one to three D4Z4 repeats (84). Similarly, hearing loss is also largely restricted to patients with one to three D4Z4 repeats (48). To that extent, FSHD is pleiotropic; that is, the genetic abnormality affects multiple organ systems in ways not understood. In adult-onset disease, however, hearing loss is not more common in people with FSHD than in the general population (70; 94; 95). Mental retardation and epilepsy are exceedingly rare (94; 28; 13).

Calf hypertrophy is distinctly unusual but has been reported (57; 33). Respiratory failure is also infrequent but should be considered a consequence in more severely affected individuals (54; 07; 110; 80; 89). More commonly, patients have a restrictive ventilatory pattern, with up to 45% with that pattern on pulmonary function studies (89). Cardiac involvement is uncommon and consists of mainly conduction abnormalities that are usually benign (39; 19; 93; 38; 14). Dysphagia is rare, even in advanced disease (110). As discussed below, carriers of the mutation may diverge from the consensus criteria for diagnosis. Also, homozygosity for the 4q35 deletion does not result in a more severe phenotype (91).

Clinical diagnostic criteria. An international workshop developed detailed diagnostic criteria for FSHD (59), which remain largely applicable (87). The major criteria that define FSHD are onset in facial or periscapular muscles sparing ocular, pharyngeal, and lingual muscles. Supporting clinical evidence of FSHD include:

	• Prominent asymmetric shoulder and facial involvement as well as weakness of abdominal muscles.
	• In early-onset FSHD, the presence of hearing loss or retinal vasculopathy is highly supportive of the diagnosis.
	• Autosomal dominant inheritance with a high frequency of sporadic cases due to de novo mutations.

The presence of severe contracture, cardiomyopathy, or symptomatic respiratory failure at the time of initial evaluation should suggest alternative diagnoses. With the availability of highly sensitive and specific genetic testing, a muscle biopsy should be performed in individuals to look for an alternative diagnosis only when genetic testing is negative and an alternative diagnosis amenable to pathologic diagnosis is being considered (56). In facioscapulohumeral muscular dystrophy, EMG and muscle biopsy usually show nonspecific myopathic patterns, and serum creatine kinase values are normal or modestly elevated (not more than five times the normal limit).

Genetic diagnosis. FSHD, in its most common form, results from a partial deletion of a large repetitive DNA element called a macrosatellite repeat. This form of FSHD, now referred to as FSHD1, represents about 95% of patients with FSHD (69). The FSHD-associated repetitive element is known as D4Z4 and is present in the subtelomeric region of the long arm of chromosome (4q35). Each D4Z4 repeat is 3.3 kb in size, and normal individuals typically have 11 to 100 D4Z4 repeats on each copy of chromosome 4q35. In FSHD1, one copy of 4q35 will have one to 10 repeats. The genetic test uses a probe that recognizes a sequence just proximal to the repeats. Subsequent digestion with the EcoRI restriction enzyme yields a DNA fragment that spans the D4Z4 array. Consequently, the fragment size reported on commercial FSHD genetic testing will vary with the number of D4Z4 repeats. Thus, normal alleles having more than 10 repeats are greater than 38 kb in size, whereas an FSHD-associated allele with one to 10 residual repeats is between 10 and 38 kb in size (56).

As mentioned above, individuals with large deletions resulting in a contracted allele have the most severe clinical manifestations. Individuals with one to two repeats tend to include patients with early onset FSHD. Patients with three to six D4Z4 repeat units are more affected than patients with seven to nine D4Z4 repeat units and are more likely to have facial involvement (53). Standard genetic testing for FSHD1 is both highly sensitive (93%) and specific (98%) (85).

About 5% of patients with clinically typical facioscapulohumeral muscular dystrophy do not have D4Z4 contractions but have severe DNA hypomethylation of both copies of 4q35 (10). This hypomethylation of 4q35 is now known to be the result of mutations in the SMCHD1 gene, a gene involved in X chromosome inactivation (41) and also associated with arhinia or Bosma arhinia microphthalmia syndrome (50) or DNA methyltransferase 3B (DNMT3B). Monoallelic DNMT3B mutation can cause facioscapulohumeral muscular dystrophy phenotype, whereas biallelic mutations cause autosomal recessive immunodeficiency, centromeric instability, and facial anomalies (ICF syndrome) (101). Ligand‐dependent nuclear receptor interacting factor 1 (LRIF1; also known as HBiX1) is associated with D4Z4 chromatin relaxation, and a carrier of homozygous mutation of this gene has been reported to have facioscapulohumeral muscular dystrophy phenotype (29). This form of facioscapulohumeral muscular dystrophy (FSHD2) is clinically identical to FSHD1. Genetic testing for FSHD1 and FSHD2 can be done in a hierarchical manner commercially.

Prognosis and complications

The disease is slowly progressive and does not shorten mortality. In a survey, 61 of 126 affected adults were currently working, only nine needed adjustments for disease-related handicaps, and 85% considered their jobs satisfying (107).

Medical complications exist. Twenty percent of patients above the age of 50 will eventually use a wheelchair. Several studies have examined pulmonary function in patients with facioscapulohumeral muscular dystrophy. Up to approximately one-third of patients or nonambulant patients may suffer from respiratory insufficiency (51; 111). The pattern on pulmonary function testing is mainly restrictive (80; 51; 111; 89). Patients with restrictive lung disease can be asymptomatic to requiring the use of noninvasive ventilation. In a single center study, the frequency of use of noninvasive ventilation was reported to be 14% (51). However, this estimate may be too high as another nationwide Dutch study found that only 1% of patients with FSHD had clinically significant respiratory failure requiring noninvasive or invasive ventilator support (113). Predisposing factors for restrictive lung disease include age of onset, D4Z4 fragment length, wheelchair dependence, pelvic girdle weakness, (kypho-)scoliosis or lumbar lordosis, and pectus excavatum (113; 80; 51; 111). Patients with predisposing factors should have periodic pulmonary function testing. Sleep-disordered breathing including hypoventilation syndrome and obstructive sleep apnea is frequent and may be subclinical (51; 74). Spinal deformities can be present in approximately 20% to 30% of patients; these are predominantly lumbar hyperlordosis or, less commonly, scoliosis, with childhood-onset cases being the most severe (57). Additionally, camptocormia due to weakness of paraspinal muscles can be seen in older patients. Up to 60% to 70% of patients can also complain of pain and difficulty sleeping with poor sleep quality (31; 35).

Severe childhood-onset FSHD typically have large deletions (ie, residual D4Z4 allele size of 10 to 18 kb) and are at higher risk of developing a potentially preventable exudative retinopathy also known as Coats disease; such patients need periodic surveillance with dilated indirect ophthalmoscopy (84). These same patients are also at risk for symptomatic hearing loss and should have routine audiometric testing. Moreover, hearing loss can be progressive, and children with large deletions should continue to be monitored even if they passed newborn hearing screening (48).

Pregnancy is usually tolerated well, but some women later have more difficulty caring for children (73; 08).

Clinical vignette

A male with no known family history of neuromuscular disease was a varsity swimmer and speed skater in college, and he had been actively athletic throughout his adult years. He had several episodes of acute low back pain, and, at 70 years of age, had paresthesias in both legs on prolonged standing and then had difficulty standing erect, especially after walking. When he shaved, he bent forward and then had difficulty standing up. Lumbar laminectomy gave no benefit, and right hip replacement helped the leg discomfort but not the difficulty standing erect, so he began using a cane. In airports he had to use a wheelchair. His social life was constricted because he could not stand. He had difficulty raising his right arm and stopped playing tennis at 72 years of age. By the age of 75 he could not raise his right arm to fix his collar or comb his hair; similar problems on the left were milder. He had difficulty rising from low seats but could go up or down stairs. He had always had difficulty blowing up balloons and whistling but did close his eyes in sleep. Past history and system review were unremarkable. There was no consanguinity in the family, and his four sons, ages 41 to 49, were all asymptomatic.

Eye closure was weak against resistance. His lips were slightly everted, and his whistle was weak. Speech was clear. Neck flexion was weak against resistance. In sitting he supported his head with his right arm, supporting the arm by leaning on the elbow. There was not an overtly typical facioscapulohumeral appearance when he was viewed from the front, but the tips of the scapulae did protrude above the clavicle. Similarly, there was no typical scapular winging, but the left scapula protruded more than the right in testing the supraspinati or in pushing against the wall. He could not raise his arms to shoulder level, but they could be stretched overhead passively without any unusual resistance. The following shoulder muscles were all strong: supraspinati, infraspinati, trapezius, and rhomboids. Similarly, there was no weakness of the deltoids, biceps, triceps, or hand muscles. He could walk on heels or toes, and could rise from a standard chair without using his hands. There was no weakness of leg muscles on manual testing. As soon as he stood to walk, he bent forward from the trunk and his head began to drop. Tendon reflexes were absent. There was no focal wasting, no Hoffmann or Babinski signs, and no clonus. Sensation was normal.

EMG was a mixed pattern, with a predominantly myopathic pattern in proximal limb muscles but some neurogenic features distally. Nerve conduction studies gave normal results except for findings compatible with asymptomatic carpal tunnel median neuropathies. Serum creatine kinase level was normal.

DNA diagnosis (Athena). After EcoRI and EcoRI-BlnI restriction endonuclease digestion, the patient had a 34 kb allele 1 and greater than 48 kb allele 2. In normal people, allele size is greater than 42 kb; borderline values are 38 to 41 kb; FSHD deletions give result in values of 10 to 38 kb. The patient’s values repeat size were clearly in the FSHD range, but there was also evidence of a translocation with 10q26, which raised some uncertainty of interpretation. However, given the clinical picture compatible with the diagnosis (despite the late onset), the DNA evidence also favored the diagnosis of FSHD. Whether this was a new mutation could not be ascertained without clinical and DNA studies of his parents.

Comment. This case history is atypical in several respects, including late onset, lack of other symptomatic relatives, and symptomatic predominance as the bent spine syndrome. All, however, have been reported, and DNA analysis proved the diagnosis.

Biological basis

Etiology and pathogenesis

Genetics. FSHD1 is inherited as an autosomal dominant disorder; it is caused by a deletion of a critical number of D4Z4 repeats on one copy of 4q35. However, the contraction is necessary but not sufficient to cause FSHD1. The contraction has to occur on a 4q35 that is of the “A” sequence variant distal to the last repeat.

Most of the remaining patients (about 5%) with typical clinical features of facioscapulohumeral muscular dystrophy have FSHD2. Patients with FSHD2 have normal number of D4Z4 repeats on both copies of 4q35 but demonstrate profound DNA hypomethylation at the D4Z4 locus (10). DNA hypomethylation indicates a more open chromatin structure, and therefore, containing genes that are more likely to be expressed. This is caused by a gene locus different than the FSHD1 4q locus. In about 80% of cases, FSHD2 is associated with mutations in the SMCHD1 gene on chromosome 18p (41) and DMNT3B gene on chromosome 20 (101). Inheritance of FSHD2 is considered digenic. FSHD2 results from the inheritance of two independent genetic predispositions: a) mutation of the SMCHD1 or DMNT3B gene, and b) the presence of at least one “A” variant distal to the D4Z4 repeats.

Molecular pathogenesis of facioscapulohumeral muscular dystrophy with DUX4 at its center

(Contributed by Dr. Leo Wang.)

Although genetically distinct, both FSHD1 and FSHD2 trigger the same molecular mechanism.

The identification of FSHD2 has also exposed another modifier of FSHD disease severity beyond the number of residual repeats. The co-occurrence of both FSHD1 and FSHD2 was identified in a family (76). In this kindred, individuals with either FSHD1 or FSHD2 associated with SMCHD1 mutations had mild disease, whereas individuals with a short (FSHD1-sized) allele and an SMCHD1 mutation had much more severe disease. Other, as yet to be uncovered, gene modifiers could account for intrafamilial variability in disease severity.

There may be a 1% to 2% prevalence of a contracted D4Z4 repeat on a permissive 4qA haplotype without an FSHD family history in the European population (11; 79). These de novo genetic changes may not be symptomatic because of the large epigenetic contribution to this disease. Penetrance (17% to 53%) appears to be correlated with smaller repeat size, lower methylation status, and age (27; 92; 77; 68; 78; 112). The smaller the repeat size, the more penetrant the disease. However, nonpenetrant mutation carriers must be distinguished from asymptomatic mutation carriers; the latter complained of no symptoms, yet on exam have mild weakness.

In 10% to 30% of patients, FSHD appears de novo (114; 102). The D4Z4 contraction occurs in the parental germline in about half of these patients and does not occur in the somatic cells. In the other half, some patients’ parents can have D4Z4 contractions that occur in some somatic cells and, therefore, have “somatic mosaicism.” The clinical severity of the mosaic FSHD1 carrier depends on the degree of mosaicism and the size of the D4Z4 repeat.

Finally, the D4Z4 repeats can be in complex repeat array structures, such as cis duplications of the D4Z4 repeat array, translocation between chromosomes 4 and 10, and rarer 4qA haplotypes (23).

Pathophysiology. The genetic lesion in FSHD is a loss of a critical number of a repetitive DNA element; therefore, there is, as such, no disruption or mutation of the sequence of an expressed gene. How a contraction of D4Z4 repeats results in FSHD remained unclear for a number of years. One critical piece of evidence was that haploinsufficiency for 4q35, deletion of one copy of the distal 4q35, does not result in FSHD. This suggested that at least one copy of D4Z4 repeat is necessary for FSHD and that the FSHD genetic defect results in a deleterious gain of function. This implied that part of the genetic sequence within repeat was essential to cause trigger disease (96). An open reading frame called DUX4, present in each D4Z4 copy, was suggested as a putative FSHD gene. However, DUX4 expression in either normal or FSHD tissue was difficult to demonstrate. Moreover, the DUX4 sequence lacked some of the components of an expressed gene, suggesting that it may be a pseudogene (30; 49; 21). Subsequently analysis of the chromatin structure also indicated that the contraction of the D4Z4 repeats changes the chromatin structure from a closed heterochromatic conformation to a more permissive euchromatic state, the latter more typically seen in expressed DNA sequences (103; 115). Finally, it was demonstrated that the subtelomeric region distal to the repeats comes in two variants or haplotypes: A or B. Contraction of a critical number of repeats on only the “A” background results in FSHD (46).

Evidence for a unifying hypothesis for the pathophysiology of FSHD emerged in 2010 from these apparently disparate findings. The hypothesis states that contraction of the repeats results in relaxation of the chromatin structure, allowing the expression of the DUX4 gene within the repeats. However, as the DUX4 sequence lacks the mRNA-stabilizing polyadenylation tail (polyA) sequence, no DUX4 protein is produced. The one exception is the DUX4 in the most distal repeat unit, which can splice the polyA sequence that is present in the “A” but not the “B” 4q35 sequence variant distal to the last repeat (44). Thus, FSHD results only if loss of a critical number of D4Z4 repeats occurs on a 4q35 allele with a distal “A” variant. This event results in the derepression of a gene, DUX4, which is normally switched off differentiated cells (83).

Although genetically different, FSHD2 appears to also be the result of reactivation of the DUX4 gene. In FSHD2, there is no contraction of the number of D4Z4 repeats, but both copies of the 4q35 D4Z4 sequences are profoundly hypomethylated, resulting in a chromatin structure that is conducive to gene expression similar to contracted D4Z4 repeat in FSHD1 (11). This DNA hypomethylation was shown to be the result of mutations in the SMCHD1 gene in most cases of FSHD2 (41) as well as DNMT3B (101). If such hypomethylation occurs in an individual with at least one “A” haplotype, DUX4 can be expressed.

Hypomethylation of the most distal D4Z4 repeat may be predictive of disease progression, time to loss of ambulation, and, less so, onset of symptoms (116).

The emerging evidence is that DUX4 is highly toxic to cells inducing apoptotic cell death, rendering cells more susceptible to oxidative stress and interfering with normal myogenesis (37; 04; 03; 82).

Differential diagnosis

Confusing conditions

Neurogenic facioscapulohumeral muscular atrophy (or spinal muscular atrophy of facioscapulohumeral distribution). This condition has been described (20), but DNA analysis indicates that it is really FSHD with inexplicably erroneous neurogenic patterns in EMG or muscle biopsy (100; 47). Misleading EMG patterns have been reported less often as recordings have improved technically and quantitative analysis of motor unit potentials has become more widely available. Since the advent of the DNA test, there have been no such reports of a neurogenic form.

Polymyositis. Two problems have caused FSHD to be confused with polymyositis. First, for reasons not known, collections of inflammatory cells may be found in the muscle biopsies of patients with typically autosomal dominant FSHD. When this is encountered in a sporadic, nonfamilial case, there may be diagnostic uncertainty. Treatment with prednisone or other immunosuppressive drugs has been used in these patients without benefit.

The other problem arises when patients with an acquired myopathy have weakness in facioscapulohumeral distribution. However, these patients do not have the typical appearance of the abnormal chest and shoulder girdle that characterizes FSHD.

Scapuloperoneal syndrome. Clinicians have been impressed by a syndrome that seems identical to FSHD, except that the face is not involved. This seems a slender reed to differentiate genetic diseases. The shoulder girdle weakness and appearance are identical to those of FSHD. It seemed that the condition could be allelic with FSHD because some individuals in typical FSHD families lack evident facial weakness. Moreover, like FSHD, the scapuloperoneal syndrome is usually myopathic and autosomal dominant; and also like FSHD, there have seemed to be neurogenic forms, and some cases did not meet criteria for autosomal dominant transmission. (X-linked families were probably instances of Emery-Dreifuss syndrome.) This issue seems to be on the road to resolution as a result of DNA analysis. Linkage to 4q35 has been excluded in several scapuloperoneal families (47; 86). Wilhelmsen and colleagues not only excluded linkage to 4q35 in one family but also found linkage of scapuloperoneal muscular dystrophy to chromosome 12, proving that this is a disorder distinct from the facioscapulohumeral disorder (109). The difference can be suspected clinically because the face is spared in all members of the family (not just a few individuals), but proof of diagnosis requires DNA analysis for linkage to 4q35 or chromosome 12. Proof for misdiagnosing the chromosome 12 scapuloperoneal muscular dystrophy led to the discovery of an X-linked scapuloperoneal dystrophy in a large Italian-American family, identifying mutations in a gene encoding four-and-a-half LIM protein 1 (FHL1) (66).

Limb-girdle muscular dystrophies. Calpainopathies (LGMDR1 or LGMD2A) have been reported to mimic the FSHD clinical phenotype as have patients with mutations in the valosin-containing protein (VCP) gene (75). The latter is often associated with Paget disease and frontotemporal dementia and has distinctive features on muscle biopsy.

Mitochondrial myopathy. Hudgson and colleagues were the first to record ragged-red fibers in a myopathy that clinically simulated FSHD; Worsfold and colleagues found evidence of impaired oxidative metabolism in that family. Rowland and colleagues described a man with a facioscapulohumeral distribution of weakness and prominent ragged-red fibers in muscle biopsy (72). There was no deletion of mitochondrial DNA, but a point mutation was not found. He had a prominent cardiomyopathy with congestive heart failure and could not stand erect because of trunk weakness; these are all features unlike FSHD. Slipetz and colleagues found deficiency of mitochondrial complex 3 in a 44-year-old woman with apparent FSHD and atrial re-entrant tachycardia (81). The shoulder girdle deformity made it difficult to keep the leads of a pacemaker in place. There were no ragged-red fibers. In another family with autosomal dominant scapulohumeral myopathy, there were no ragged red fibers, and the finding of a point mutation in an affected person may not have been decisive (62).

Emery-Dreifuss muscular dystrophy. This condition is characterized and defined by distinctive clinical features: cardiac arrhythmia (especially atrial paralysis requiring insertion of a pacemaker); contractures at elbows, knees, ankles, and spine; lack of facial weakness; and X-linked inheritance. None of these features is found in FSHD, and there should be no problem in this distinction. Occasionally, Emery-Dreifuss muscular dystrophy appears in successive generations to suggest autosomal dominant inheritance. Even then, however, the clinical features that define this disorder differ from those of FSHD.

Other myopathies. Individual cases have been reported of other myopathies simulating the facioscapulohumeral distribution of weakness. Among those diseases are inclusion-body myositis, desmin-storage myopathy, centronuclear myopathy, and acid maltase deficiency. Each of these conditions is defined by specific morphologic changes on muscle biopsy.

Diagnostic workup

The diagnosis of FSHD is usually evident clinically and confirmed by genetic testing. If there is doubt as to whether the condition is myopathic or neurogenic, a serum creatine kinase and EMG are helpful. Serum creatine kinase value should not be more than 10 times normal unless there is some complicating feature. In patients with infantile or early childhood–onset FSHD, the presence of hearing loss or retinal vascular disease is supportive of the diagnosis of FSHD. A muscle biopsy is not needed for the diagnosis of FSHD. A biopsy is necessary if genetic testing is negative to rule out an alternative diagnosis.

A diagnostic algorithm of genetic analysis has been described in European best practice guidelines based on clinical phenotype and genetic testing (23). This testing algorithm recommends further steps in testing based on (atypical versus typical) clinical phenotypes along with degree of severity. Blood cells from patients are analyzed for the D4Z4 repeat size with Southern blot after linear gel electrophoresis (SB-LGE), or for repeat size and the A/B haplotypes with Southern blot after pulsed field gel electrophoresis (SB-PFGE), optical genomic mapping, or molecular combing (which will reveal more complicated D4Z4 genomic structures). If SB-LGE is used for initial testing, the next step includes methylation assay or haplotype testing depending on D4Z4 size and phenotype if FSHD1 is not established. Then, in selected cases with permissive A haplotype in which D4Z4 contraction is not identified and methylation is normal, additional evaluation for more complex alleles with Southern blot after pulsed field gel electrophoresis, optical genomic mapping, or molecular combing may be pursued. Abnormal results on methylation assay prompts a search for FSHD2-associated gene mutations. Southern blot after pulsed field gel electrophoresis, optical genomic mapping, or molecular combing are looking for more complicated D4Z4 genomic structures that can be the result of translocations between 4q35 and 10q26 (43), somatic mosaicism, and duplication of the D4Z4 region, with a noncontracted D4Z4 region obscuring a contracted D4Z4 region on the same chromosome (45).

Management

With education, training, and emotional support, many patients are active in diverse occupations. AAN evidence-based guidelines now provide a basis for the uniform management of FSHD and its potential complications (85). The guidelines address several relevant issues, including exercise, scapular fixation, pain management, and respiratory compromise.

Clinicians may worry about exercising weak muscles. Trials have shown improvement in aerobic capacity with aerobic exercise training, though little to no improvement in dynamic strength (105).

For those with severe limitation of arm functions, surgical scapular fixation can improve shoulder range of motion. In one series, 12 patients were followed for 3 to 21 years after surgery (06; 32; 97; 01; 67; 22). All but one were pleased with the improved abduction and better performance in lifting and carrying objects. Two patients had adverse effects: transient brachial plexus palsy in the first and a frozen shoulder in the second. Other adverse effects include pleural effusion, atelectasis, scapular fractures, and rib fractures (02). Others have reported favorable results (32; 12; 67; 18). In other series, patients expressed satisfaction with the cosmetic effects as well as improved function (32; 97; 01; 22). Erşen and colleagues found that the beneficial effect on shoulder range of motion persists with time. There appears to be a minor but significant complication rate that requires surgical revision (18). Orrell and colleagues concluded that a controlled trial of scapular fixation could not be done (55). Based on the fairly weak level of evidence, the AAN guidelines recommend a cautious approach to scapular fixation (85). Before recommending scapular fixation, the potential improvement in shoulder range of motion can be assessed by bedside manual fixation of the scapula to see what gain in range of motion fixation might achieve. Additionally, the overall rate of disease progression in the individual and the muscle strength in the targeted arm need to be considered.

Because symptomatic retinal vascular disease and hearing loss are now known to be limited to patients with large deletions (ie, residual D4Z4 allele size of 10 to 18 kb), screening for these complications should be limited to this subgroup of patients with FSHD. Severe retinal vascular disease can lead to a potentially preventable exudative retinopathy also known as Coats disease. Such patients need periodic surveillance with dilated indirect ophthalmoscopy (84; 85). Similarly, patients with large deletions are predisposed to hearing loss. Audiometric testing is especially important in infants and young children as, if not detected and treated early, hearing loss can lead to delayed language development (48; 85).

Although significant respiratory compromise is relatively uncommon, clinicians should be vigilant in patients with the predisposing factors listed above who should have routine measurement of their FVC and asked about symptoms of nocturnal hypoventilation, such as orthopnea, non-restful sleep, frequent nightmares, and early-morning headaches. All patients should have baseline pulmonary function testing done, and those with signs of restrictive lung disease (FVC < 60% predicted) and with predisposing factors should have regular pulmonary function testing (85).

Pain is a commonly reported symptom by patients, both children and adults (13; 35). Clinicians should ask about and monitor patient’s pain and discuss risks and benefits of physical therapy or pharmacological interventions. Fatigue is also a commonly reported symptom and may be also intertwined with pain.

A systematic literature review and retrospective study demonstrated no evidence of cardiac structural involvement (85; 38; 14). Additionally, the evidence for the predilection of patients with FSHD to atrial arrhythmias is insufficient to reliably determine its frequency but is likely very low. As such, no routine cardiac testing is needed unless a patient is symptomatic.

Drug therapy aimed at nonspecific enhancement of muscle function has been largely ineffective (71; 17; 108). Based on the lack of evidence of efficacy, the AAN guidelines do not recommend the use of any of the drugs studied (prednisone, albuterol, diltiazem) for the treatment of muscle weakness in facioscapulohumeral muscular dystrophy (85). The results of a 17-week randomized placebo-controlled trial of an antioxidants cocktail have been published (64). There was no significant change in the primary outcome—the 2-minute walk, but there were modest improvements in some secondary outcome measures.

There are currently at least four proposed mechanisms of action of treatments targeting FSHD. The first continues nonspecific enhancement of muscle function with one approach targeting the myostatin pathway. The second targets the activation of DUX4 transcription factor with a p38 protein kinase inhibitor or a beta-agonist. Losmapimod, a p38 protein kinase inhibitor, is the most advanced candidate, having completed a phase 2 study (88) and currently completing a phase 3 study. The third negates the production of the DUX4 RNA with antisense oligonucleotides or short interfering RNAs attached to muscle-specific honing signals. The fourth acts on silencing the genomic structure of the 4q35 chromosome by increasing the methylation at that site. These treatments differ in the delivery mechanism (orally available small molecule versus infusion of [synthetic] protein/peptides conjugated to nucleotide-like chemicals versus viral vector delivery), frequency, risk, and cost.

The identification of DUX4 misexpression as the primary cause of FSHD has provided a targeted approach to the treatment of FSHD, and clinical research activity in this field is exciting (90).

References

01: Andrews CT, Taylor TC, Patterson VH. Scapulothoracic arthrodesis for patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1998;8:580-4. PMID 10093065
02: Berne D, Laude F, Laporte C, Fardeau M, Saillant G. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy. Clin Orthop Relat Res 2003;409:106-13. PMID 12671492
03: Bosnakovski D, Daughters RS, Xu Z, Slack JM, Kyba M. Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS One 2009;4(9):e7003. PMID 19756142
04: Bosnakovski D, Xu Z, Gang EJ, et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J 2008;27(20):2766-79. PMID 18833193
05: Brouwer OF, Padberg GW, Bakker E, Wijmenga C, Frants RR. Early onset of facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;(Suppl 2):S67-72. PMID 23573589
06: Bunch WH, Siegel IM. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy: review of seventeen procedures with three to twenty-one-year follow-up. J Bone Joint Surg 1993;75:372-6. PMID 8444915
07: Carter GT, Bird TD. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2005;64(2):401. PMID 15668464
08: Ciafaloni E, Pressman EK, Lori AM, et al. Pregnancy and birth outcomes in women with facioscapulohumeral muscular dystrophy. Neurology 2006;67(10):1887-9. PMID 17130433
09: Deenen JC, Arnts H, van der Maarel SM, et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 2014;83(12):1056-9. PMID 25122204
10: de Greef JC, Lemmers RJ, Camaño P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010;75:1548-54. PMID 20975055
11: de Greef JC, Lemmers RJ, van Engelen BJ, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 2009;30(10):1449-59. PMID 19728363
12: Diab M, Darras BT, Shapiro F. Scapulothoracic fusion for facioscapulohumeral muscular dystrophy. J Bone Joint Surg Am 2005;87(10):2267-75. PMID 16203893
13: Dijkstra JN, Goselink RJM, van Alfen N, et al. Natural history of facioscapulohumeral dystrophy in children: a 2-year follow-up. Neurology 2021;97(21): e2013-13. PMID 34675094
14: Ducharme-Smith A, Nicolau S, Chahal CAA, et al. Cardiac involvement in facioscapulohumeral muscular dystrophy. Front Neurol 2021;12:668180. PMID 34108930
15: Duchenne GB. Album de photographies pathologiques complementaire de liver intule de l'electrisation localisee. Paris: JB Bailliere, 1862.
16: Eger K, Jordan B, Habermann S, Zierz S. Beevor's sign in facioscapulohumeral muscular dystrophy: an old sign with new implications. J Neurol 2010;257(3):436-8. PMID 19838767
17: Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, Kissel JT. Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. Neurology 2007;68(17):1428-9. PMID 17452589
18: Ersen A, Atalar AC, Bayram S, Demirel M, Tunali O, Demirhan M. Long-term results of scapulothoracic arthrodesis with multiple cable method for facioscapulohumeral dystrophy. Bone Joint J 2018;100-B(7):953-6. PMID 29954200
19: Finsterer J, Stollberger C, Meng G. Cardiac involvement in facioscapulohumeral muscular dystrophy. Cardiology 2005;103(2):81-3. PMID 15550754
20: Furukawa T. Neurogenic FSH muscular atrophy. Muscle Nerve 1995;(Suppl 2):S96-7. PMID 23573593
21: Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 1999;236(1): 25-32. PMID 10433963
22: Giannini S, Faldini C, Pagkrati S, et al. Fixation of winged scapula in facioscapulohumeral muscular dystrophy. Clin Med Res 2007;5(3):155-62. PMID 18056023
23: Giardina E, Camano P, Burton-Jones S, et al. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: update of the 2012 guidelines. Clin Genet 2024;106(1):13-26. PMID 38685133
24: Goselink RJM, Schreuder THA, van Alfen N, et al. Facioscapulohumeral dystrophy in childhood: a nationwide natural history study. Ann Neurol 2018a;84(5):627-37. PMID 30179273
25: Goselink RJM, van Kernebeek CR, Mul K, et al. A 22-year follow-up reveals a variable disease severity in early-onset facioscapulohumeral dystrophy. Eur J Paediatr Neurol 2018b;22(5):782-5. PMID 29753614
26: Goselink RJM, Voermans NC, Okkersen K, et al. Early onset facioscapulohumeral dystrophy – a systematic review using individual patient data. Neuromuscul Disord 2017;27(12):1077-83. PMID 29102079
27: Goto K, Nishino I, Hayashi Y. Very low penetrance in 85 Japanese families with facioscapulohumeral muscular dystrophy 1A. J Med Genet 2004;41(1):e12. PMID 14729852
28: Grosso S, Mostardini R, Di Bartolo RM, Balestri P, Verrotti A. Epilepsy, speech delay, and mental retardation in facioscapulohumeral muscular dystrophy. Eur J Paediatr Neurol 2011;15(5):456-60. PMID 21763164
29: Hamanaka K, Sikrova D, Mitsuhashi S, et al. Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology 2020;94(23):e2441-7. PMID 32467133
30: Hewitt JE, Lyle R, Clark LN, et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 1994;3(8):1287-95. PMID 7987304
31: Hoffmann HM, Malo-Juvera V, Statland JM. Self-reported reduced sleep quality and excessive daytime sleepiness in facioscapulohumeral muscular dystrophy. Muscle Nerve 2022;66(4):487-94. PMID 35893768
32: Jakab E, Gledhill RB. Simplified technique for scapulocostal fusion in facioscapulohumeral dystrophy. J Pediatr Orthop 1993;13:749-51. PMID 8245200
33: Jardine PE, Jones M, Tyfield L, Upadhyaya M, Lunt P. De novo DNA rearrangement in atypical facioscapulohumeral muscular dystrophy. Clin Genet 1993;44(3):167. PMID 8275579
34: Justin-Bescanon L, Pequignot H, Contamin F, Delavierre P, Rolland P. Myopathie du type Landouzy-Dejerine. Rapport d'une observation historique. Sem Hop 1964;40:2990-9. PMID 14257214
35: Kelly CR, Saw JL, Thapa P, Mandrekar J, Naddaf E. Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort. Muscle Nerve 2022;65(4):415-21. PMID 35020192
36: Kohler J, Rupuilius B, Otto M, Bathke K, Koch MC. Germline mosaicism in 4q35 facioscapulohumeral muscular dystrophy (FSHD1A) occurring predominantly in oogenesis. Hum Genet 1996;98:485-90. PMID 8792827
37: Kowalijow V, Marcowycz A, Ansseau E, et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 2007;17(8):611-23. PMID 17588759
38: Labombarda F, Maurice M, Simon JP, et al. Cardiac abnormalities in type 1 facioscapulohumeral muscular dystrophy. J Clin Neuromuscl Dis 2017;18(4):199-206. PMID 28538250
39: Laforet P, de Roma C, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology 1998;51:1454-6. PMID 9818880
40: Landouzy L, Dejerine J. De la myopathie atrophique progressive. Rev Med Franc 1885;5:81-253.
41: Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44(12):1370-4. PMID 23143600
42: Lemmers RJ, van der Wielen MJ, Bakker E, Frants RR, van der Maarel SM. Rapid and accurate diagnosis of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2006;16(9-10): 615-7. PMID 16938455
43: Lemmers RJ, van der Vliet PJ, Blatnik A, et al. Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene. J Med Genet 2022;59(2):180-8. PMID 33436523
44: Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329(5999):1650-3. PMID 20724583
45: Lemmers RJ, van der Vliet PJ, Vreigling JP, et al. Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. Hum Mol Genet 2018;27(20):3488-97. PMID 30281091
46: Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet 2007;81(15):884-94. PMID 17924332
47: Lunt PW, Harper PS. Genetic counseling in facioscapulohumeral muscular dystrophy. J Med Genet 1991;28:655-64. PMID 1941962
48: Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology 2013;81(16):1374-7. PMID 24042093
49: Lyle R, Wright TJ, Clark LN, Hewitt JE. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. Genomics 1995;28(3):389-97. PMID 7490072
50: Mohassel P, Chang N, Inoue K, et al. Cross-sectional, neuromuscular phenotyping study of arhinia patients with SMCHD1 variants. Neurology 2022;98(13):e1384-96. PMID 35121673
51: Moreira S, Wood L, Smith D, et al. Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. J Neurol 2017;264(6):1271-80. PMID 28550484
52: Mul K. Facioscapulohumeral muscular dystrophy. Continuum (Minneap Minn) 2022;28(6):1735-51. PMID 36537978
53: Mul K, Voermans NC, Lemmers RJLF, et al. Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1. Clin Genet 2018;94(6):521-7. PMID 30211448
54: Nakagawa M, Higuchi I, Yshidome H, et al. Familial facioscapulohumeral muscular dystrophy: phenotypic diversity and genetic abnormality. Acta Neurol Scand 1996;93:189-92. PMID 8741141
55: Orrell RW, Copeland S, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev 2010;(1):CD003278. PMID 20091543
56: Orrell RW, Tawil R, Forrester J, Kissel JT, Mendell JR, Figlewicz DA. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology 1999;52:1822-6. PMID 10371529
57: Padberg GW. Facioscapulohumeral disease (thesis). Leiden: University of Leiden, 1982.
58: Padberg GW, Brouwer OF, deKeizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;(Suppl 2):S73-80. PMID 23573590
59: Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1991;1(4):231-4. PMID 1822799
60: Padberg GW, van Engelen BG. Facioscapulohumeral muscular dystrophy. Curr Opin Neurol 2009;22(5):539-42. PMID 19724227
61: Pagola-Lorz I, Vicente E, Ibáñez B, et al. Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Orphanet J Rare Dis 2019;14(1):276. PMID 31791368
62: Pal E, Bedekovics T, Gati I. Familial scapuloperoneal myopathy and mitochondrial DNA defect. Eur Neurol 1999;42:211-6. PMID 10567817
63: Park HJ, Hong JM, Lee JH, et al. Low D4Z4 copy number and gender difference in Korean patients with facioscapulohumeral muscular dystrophy type 1. Neuromuscul Disord 2015;25(11):859-64. PMID 26319123
64: Passerieux E, Hayot M, Jaussent A, et al. Effects of vitamin C, vitamin E, zinc gluconate and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial. Free Radic Biol Med 2015;81:158-69. PMID 25246239
65: Pradhan S. Poly-hill sign in facioscapulohumeral muscular dystrophy. Muscle Nerve 2002;25:754-5. PMID 11994973
66: Quinzii CM, Vu TH, Min C, et al. X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half LIM protein 1. Am J Hum Genet 2008;82(1):208-13 PMID 18179901
67: Rhee YG, Ha JH. Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy. J Shoulder Elbow Surg 2006;15(4):445-50. PMID 16831649
68: Ricci G, Scionti I, Sera F, et al. Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain 2013;136(Pt 11):3408-17. PMID 24030947
69: Rieken A, Bossler AD, Mathews KD, Moore SA. CLIA laboratory testing for facioscapulohumeral dystrophy: a retrospective analysis. Neurology 2021;96(7):e1054-62. PMID 33443126
70: Rogers MT, Zhao F, Harper PS, Stephens D. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2002;12(4):358-65. PMID 12062253
71: Rose MR, Tawil R. Drug treatment for facioscapulohumeral muscular dystrophy. Cochrane Database Syst Rev 2004;(2):CD002276. PMID 15106171
72: Rowland LP, Blake DM, Hirano M, et al. Clinical syndromes associated with ragged red fibers. Rev Neurol 1991;147:467-73. PMID 1962052
73: Rudnik-Schoneborn S, Glauner B, Rohrig D, Zerres K. Obstetric aspects in women with facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and congenital myopathies. Arch Neurol 1997;54:888-94. PMID 9236578
74: Runte M, Spiesshoefer J, Heidbreder A, et al. Sleep-related breathing disorders in facioscapulohumeral dystrophy. Sleep and breathing 2019;23(3):899-906. PMID 31025273
75: Sacconi S, Camaño P, de Greef JC, et al. Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity. J Med Genet 2012;49:41-6. PMID 21984748
76: Sacconi S, Lemmers RJ, Balog J, et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet 2013;93(4):744-51. PMID 24075187
77: Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic mani- festation in FSHD Greek patients. Neuromuscul Disord 2012;22(4):339-49. PMID 26925213
78: Salort-Campana E, Nguyen K, Bernard R, et al. Low penetrance in facioscapulo- humeral muscular dystrophy type 1 with large pathological D4Z4 alleles: a cross- sectional multicenter study. Orphanet J Rare Dis 2015;10:2. PMID 25603992
79: Scionti I, Fabbri G, Fiorillo C, et al. Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic coun- selling. J Med Genet 2012;49(3):171-8. PMID 22217918
80: Scully MA, Eichinger KJ, Donlin-Smith CM, Tawil R, Statland JM. Restrictive lung involvement in facioscapulohumeral muscular dystrophy. Muscle Nerve 2014;50(5):739-43. PMID 24639337
81: Slipetz DM, Aprille JR, Goodyer ER, et al. Deficiency of complex III of the mitochondrial respiratory chain in a patient with facioscapulohumeral disease. Am J Hum Genet 1991;48:502-10. PMID 1847791
82: Snider L, Asawachaicharn A, Tyler AE, et al. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 2009;18(13):2414-30. PMID 19359275
83: Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 2010;6(10):e1001181. PMID 21060811
84: Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology 2013;80(13):1247-50. PMID 23446679
85: Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2015;85(4):357-64. PMID 26215877
86: Tawil R, Myers GJ, Weiffenbach B, Griggs RC. Scapuloperoneal syndromes. Absence of linkage to the 4q35 FSHD locus. Arch Neurol 1995;52(11):1069-72. PMID 7487558
87: Tawil R, van der Maarel S, Padberg G, van Engelen BG. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2010; 20(7):471-5. PMID 20554202
88: Tawil R, Wagner KR, Hamel JI, et al. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 2024;23(5):477-86. PMID 38631764
89: Teeselink S, Vincenten SCC, Voermans NC, et al. Long‐term follow‐up of respiratory function in facioscapulohumeral muscular dystrophy. J Neurology 2022;1-8. PMID 35147730
90: Tihaya MS, Mul K, Balog J, et al. Facioscapulohumeral muscular dystrophy: the road to targeted therapies. Nat Rev Neurol 2023;19(2):91-108. PMID 36627512
91: Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004a;14:33-8. PMID 14659410
92: Tonini MM, Pavanello RC, Gurgel-Giannetti J, et al. Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more sever phenotype. J Med Genet 2004b;41(2):e17. PMID 14757867
93: Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol 2006;56(1):1-5. PMID 16804309
94: Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol 2008a;13(1):1-6. PMID 17715463
95: Trevisan CP, Pastorello E, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy; hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol 2008b;15(12):1353-8. PMID 19049553
96: Tupler R, Berardinelli A, Barbierato L, et al. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J Med Genet 1996;33(5):366-70. PMID 8733044
97: Twyman RS, Harper GD, Edgar MA. Thoracoscapular fusion in facioscapulohumeral muscular dystrophy: clinical review of a new surgical method. J Shoulder Elbow Surg 1996;5:201-5. PMID 8816339
98: Tyler FH, Stephens FE. Studies in disorders of muscle. II. Clinical manifestations and inheritance of facioscapulohumeral muscular dystrophy. Ann Int Med 1950;32(4):640-60. PMID 15411118
99: Upadhyaya M, Cooper DN, editors. Facioscapulohumeral muscular dystrophy. Clinical medicine and molecular cell biology. Oxford: Garland Science BIOS Scientific Publishers, 2004.
100: Upadhyaya M, Lunt PW, Sarfarazi M, et al. DNA marker applicable to presymptomatic and prenatal diagnosis of facioscapulohumeral disease. Lancet 1990;336:1320-1. PMID 1978143
101: van den Boogaard ML, Lemmers RJLF, Balog J, et al. Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy. Am J Hum Genet 2016;98(5):1020-9. PMID 27153398
102: van der Maarel SM, Deidda G, Lemmers RJ, et al. De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10. Am J Hum Genet 2000;66(1):26-35. PMID 10631134
103: van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003;35(4):315-7. PMID 14634647
104: Vincenten SCC, Van Der Stoep N, Paulussen ADC, et al. Facioscapulohumeral muscular dystrophy—reproductive counseling, pregnancy, and delivery in a complex multigenetic disease. Clin Gen 2022;101(2):149-60. PMID 34297364
105: Voet NB, van der Kooi EL, van Engelen BG, Geurts AC. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 2019;12(12):CD003907. PMID 31808555
106: Wang Z, Qiu L, Lin M, et al. Prevalence and disease progression of genetically-confirmed facioscapulohumeral muscular dystrophy type 1 (FSHD1) in China between 2001 and 2020: a nationwide population-based study. Lancet Reg Health West Pac 2022;18:100323. PMID 35024656
107: Wevers CW, Brouwer OF, Padberg GW, Nijboer ID. Job perspectives in facioscapulohumeral muscular dystrophy. Disabil Rehabil 1993;15(1):24-8. PMID 8431588
108: Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63(5):561-71. PMID 18335515
109: Wilhelmsen KC, Blake DM, Lynch T, et al. Chromosome 12-linked autosomal dominant scapuloperoneal muscular dystrophy. Ann Neurol 1996;39(4):507-20. PMID 8619529
110: Wohlgemuth M, de Swart BJ, Kalf JG, Joosten FB, van der Vliet AM, Padberg GW. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology 2006;66(12):1926-8. PMID 16801662
111: Wohlgemuth M, Horlings CGC, van der Kooi EL, et al. Respiratory function in facioscapulohumeral muscular dystrophy 1. Neuromuscul Disord 2017;27(6):526-30. PMID 28416348
112: Wohlgemuth M, Lemmers RJ, Jonker M, et al. A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1. Neurology 2018;91(5):e444-54. PMID 29997197
113: Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2004;63(1):176-8. PMID 15249635
114: Zatz M, Marie SK, Passos-Bueno MR, et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 1995;56(1):99-105. PMID 7825608
115: Zeng W, de Greef JC, Chen YY, et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesion binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 2009;5(7):e1000559. PMID 19593370
116: Zheng F, Qiu L, Chen L, et al. Association of 4qA-specific distal D4Z4 hypomethylation with disease severity and progression in facioscapulohumeral muscular dystrophy. Neurology 2023;101(3):e225-37. PMID 37225433

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Leo H Wang MD PhD

Dr. Wang of the University of Washington School of Medicine received consulting fees from Fulcrum Therapeutics and research support from Avidity and Fulcrum Therapeutics.
See Profile
Matthew Preston MD

Dr. Preston of the University of Washington has no relevant financial relationships to disclose.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Rabi Tawil MD
Emma Ciafaloni MD FAAN
Michael K Hehir MD

Patient Profile

Age range of presentation: 0 month to 80 years
Sex preponderance: male=female
Heredity: heredity may be a factor

heredity typical

autosomal dominant (FSHD1), digenic (FSHD2)
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Facioscapulohumeral dystrophy: G71.0
ICD-11: Facioscapulohumeral muscular dystrophy: 8C70.3
OMIM: Facioscapulohumeral dystrophy: #158900

Scapuloperoneal muscular dystrophy: #181430

Limb-girdle muscular dystrophy (AR): #253600

Limb-girdle muscular dystrophy (AD): #159000

Distal muscular dystrophy (AD): #160500

Distal muscular dystrophy (AR): #254130

Emery-Dreifuss muscular dystrophy: #310300

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Facioscapulohumeral muscular dystrophy

Associated Disorders

Coats disease
Emery-Dreifuss muscular dystrophy
Facioscapulohumeral muscular dystrophy with inflammatory lesions in muscle
High-frequency hearing loss
Mitochondrial myopathy
- Neurogenic facioscapulohumeral muscular dystrophy spinal muscular atrophy
- Retinopathy
- Scapuloperoneal muscular dystrophy
- Scapuloperoneal syndrome

Differential Diagnosis

congenital facial palsy
Möbius syndrome
polymyositis
scapuloperoneal syndrome
limb-girdle muscular dystrophies
- mitochondrial myopathy
- Emery-Dreifuss muscular dystrophy
- inclusion-body myositis
- desmin-storage myopathy
- centronuclear myopathy

Also Relevant

Congenital muscle fiber-type disproportion
Desmin body myofibrillar myopathy
Distal myopathies
Emery-Dreifuss muscular dystrophy
Limb-girdle muscular dystrophies
- Mobius syndrome
- Neuromuscular pathology: overview
- Polymyositis and fasciitis
- Spinal muscular atrophy

Clinical Categories

Neuromuscular Disorders

Patient Handouts

Web References

Guidelines

AAN: Neuromuscular guidelines

Facioscapulohumeral muscular dystrophy (FSH) …

Facioscapulohumeral muscular dystrophy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Drug-induced myasthenic syndromes

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

Facioscapulohumeral muscular dystrophy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Asymptomatic hyperCKemia

Limb-girdle muscular dystrophies

Chronic progressive external ophthalmoplegia

Drug-induced myasthenic syndromes

Distal myopathies

Amyotrophic lateral sclerosis

ALS-like disorders of the Western Pacific

This is an article preview.
Start a Free Account
to access the full version.